Primary Malignant Liver Neoplasm

Mutation of ARID2 in Hepatocellular Carcinoma (HCC) is often seen. There is about 6/16 of the truncated mutations found at the C2H2 domain (zinc finger) and about 16/24 mutations show that this domain… (full text at CIViC)

PMID 32071245 · Jiang et al., 2020 · Open in CIViC

Two cases of patients with BRAF V600E positive, refractory intrahepatic cholangiocarcinoma showed excellent clinical and radiographic response to combination dabrafenib and trametinib treatment. One p… (full text at CIViC)

PMID 28078132 · Lavingia et al., 2016 · Open in CIViC

Dabrafenib and trametinib combination showed durable response for a patient with standard chemotherapy and radiation refractory, poorly differentiated, intrahepatic cholangiocarcinoma harboring BRAF V… (full text at CIViC)

PMID 25435907 · Loaiza-Bonilla et al., 2014 · Open in CIViC

In a meta-analysis including nine trials with a total of 942 patients, high CD44v6 expression is significantly associated with a decrease in survival outcome (HR 2.13, 95% CI: 1.58 to 2.88).

PMID 25887688 · Fu et al., 2015 · Open in CIViC

This preclinical study elucidated the potential varying efficaciousness of cyclin dependent Kinase inhibitor (CDK) dinaciclib. When forcing overexpression of differing CDKs (CDK1 and 9). Overall Hepat… (full text at CIViC)

PMID 31561409 · Shao et al., 2019 · Open in CIViC

In a clinical study including 128 patients, CEACAM1-L dominant expression is significantly associated with decreased recurrence-free survival rate by a multivariate analysis (p = 0.04). Moreover CEACA… (full text at CIViC)

PMID 24390710 · Kiriyama et al., 2014 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

The authors analyzed 52 hepatoblastoma (HB) biopsies and three HB cell lines from sporadic HBs and found 48% of them bearing mutations on beta-catenin exon 3, which encodes the degradation targeting… (full text at CIViC)

PMID 9927029 · Koch et al., 1999 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

Five mutations resulted in amino acid substitutions in codons 32 and 34, suggesting an influence on the accessibility of the serine 33 for the GSK-3β kinase, preventing its phosphorylation (Fig. 2a)

PMID 9927029 · Koch et al., 1999 · Open in CIViC

The evidence from the literature describes the association of CTNNB1 mutation to Hepatoblastoma (HB) via detecting CTNNB1 mutation in HB cell lines through molecular techniques. In conclusion, 78% (21… (full text at CIViC)

PMID 12101426 · Taniguchi et al., 2002 · Open in CIViC

Of 39 hepatoblastoma samples, 10 tumor samples had point mutations in exon 3 of beta-catenin gene. One mutation changes threonine at position 41 to alanine (T41A).

PMID 16937357 · Sugawara et al., 2007 · Open in CIViC

RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional … (full text at CIViC)

PMID 25698061 · Graham et al., 2015 · Open in CIViC

A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion wa… (full text at CIViC)

PMID 24578576 · Honeyman et al., 2014 · Open in CIViC

The ctDNA of 46 patients with hepatocellular carcinoma was analyzed to investigate whether EGFR alterations could lead to lenvatinib resistance. Among these patients, 16 had been treated with lenvatin… (full text at CIViC)

PMID 36708791 · Lim et al., 2023 · Open in CIViC

In a retrospective study of 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, FGF19 copy-number gain (defined as ≥5 copies) was detected in 2/6 (33.3%) patients with complete… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

In a study with a panel of 40 HCC cell lines and 30 HCC PDX model showed that FGF19 expression is a predictive biomarker for H3B-6527. H3B-6527 is a highly selective covalent FGFR4 inhibitor.

PMID 29247039 · Joshi et al., 2017 · Open in CIViC

In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once … (full text at CIViC)

PMID 31575541 · Kim et al., 2019 · Open in CIViC

FGF3/FGF4 amplification was observed in around 2% of HCCs. Although the sample size was relatively small, FGF3/FGF4 amplification, a poorly differentiated histological type, and multiple lung metastas… (full text at CIViC)

PMID 22890726 · Arao et al., 2013 · Open in CIViC

In a retrospective analysis of sorafenib-treated hepatocellular carcinoma, FGF3/FGF4 co-amplification was detected in 3 of 10 evaluable tumors from patients with complete or partial responses and in 0… (full text at CIViC)

PMID 22890726 · Arao et al., 2013 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored the FGFR1 S602F kinase-domain mutation achieved a complete response. FGFR1 S602F was … (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-ACOT11 fusion achieved a partial response to erdafitinib, with a 49.6% maximum reduction in… (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

In the phase II NCI-MATCH EAY131-K2 trial, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-AHCYL1 fusion achieved a partial response to erdafitinib, with a 66.7% maximum reduction in… (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR2 M538I achieved a partial response. The same tumor also harbored FGFR4 G665E, pr… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

Patients with high FGFR2 expression had an overall survival rate of 72.2,40.6% at 1,3 years (p<0.05) and those with low FGFR2 expression had a 1,3 year survival rate of 92.0,82.8% (p<0.05). The diseas… (full text at CIViC)

PMID 20798558 · Harimoto et al., 2010 · Open in CIViC

FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly short… (full text at CIViC)

PMID 25834803 · Lee et al., 2015 · Open in CIViC

Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC)

PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC

In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

The phase II NCI-MATCH trial (EAY131) subprotocol W assessed the FGFR1-3 selective TKI AZD-4547 in 48 patients with FGFR1/2 amplifications, FGFR2/3 SNV or FGFR1/3 fusions. The partial response overall… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR4 G665E achieved a partial response. The same tumor also harbored FGFR2 M538I, pr… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

From October 2015 to April 2019, 103 HCC patients scheduled to receive chemoembolization were screened. Of them, 84 met inclusion criteria and were assigned to TT (TACE) (n = 25), Non-TT (TACE) (n = 3… (full text at CIViC)

PMID 34982369 · Chen et al., 2022 · Open in CIViC

Intrahepatic cholangiocarcinomas of patients with homozygous TT genotypes revealed a higher proliferation rate and a lower apoptotic rate.This study demonstrated a significant association of both dise… (full text at CIViC)

PMID 17356712 · Schmitz et al., 2007 · Open in CIViC

Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, this work found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the… (full text at CIViC)

PMID 27231123 · Saha et al., 2016 · Open in CIViC

JAK1 mutations were identified by sequencing 60 HCC PDX tumour models. There mutations were then functionally characterized. HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

JAK1 mutations were identified by sequencing 60 HCC PDX tumour models. There mutations were then functionally characterized. HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

JAK1 mutations were identified by sequencing 60 HCC PDX tumour models. There mutations were then functionally characterized. HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX mod… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR. This expression was absent in the normal tissues of these patient… (full text at CIViC)

PMID 26674738 · Sun et al., 2015 · Open in CIViC

Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was per… (full text at CIViC)

PMID 25294897 · Lim et al., 2014 · Open in CIViC

IHC was performed in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues for protein expression of HEF1 (NEDD9). Overexpression of HEF1 protein was observed in HCC tissue when… (full text at CIViC)

PMID 26893853 · Li et al., 2016 · Open in CIViC

The frequent deletion of PBLD in HCC tissues is an independent predictor of poor prognosis for patients with HCC. Elevated PBLD expression has been show to reduce the growth and spread of HCC.

PMID 26594798 · Li et al., 2016 · Open in CIViC

CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) wer… (full text at CIViC)

PMID 22596232 · Hagiwara et al., 2012 · Open in CIViC